Biotech
A Report from BIO-Europe Spring 2017
The blue skies and balmy weather of Barcelona were the perfect backdrop for BIO-Europe Spring this year. The 2,400 biotech pros at the conference...
Report from J.P. Morgan 2017
So, that’s the J.P. Morgan Healthcare Conference done for another year. For just a few highly energised days it felt as if nearly every...
LEAP HR Life Sciences: HR with Impact and Agile Biotechs
Last week RSA attended LEAP HR: Life Sciences in Boston, Massachusetts. From past experience we were expecting a high value event and we were not disappointed....
What next for EU and UK biotech boards?
In light of the UK’s decision to leave the EU, it’s worth revisiting our recent Talent Equity® report on what makes successful biotech boards. The question...
New study looks at the impact of boards on biotech company performance
UK companies performing less well than those in mainland Europe RSA has published the latest of its Talent Equity® reports, an analysis of biotech company...
Report from JP Morgan 2016
The ‘Salmon Run’ of the life sciences is over for another year. Here are some take home messages. Public funding is uncertain but institutional investor coffers are full The withdrawal...
Talent equity is the long term value of biotech
Valuation of IP is familiar to every investor in the biotech sector and careful due diligence is essential before putting money at risk. We...
Talent: the key to biotech value creation
Everyone’s happy to talk about how important talent is to tech and life sciences companies but when it comes to valuation the financial community...
New management talent needed to support biotech renaissance
2014 saw VCs plough $6.55bn into the biotech sector, with Europe alone seeing a year-on-year increase of $1.24bn. The figures tell a story of...